LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.
| Website | http://www.labgeniustx.com |
| Employees | 71 (50 on RocketReach) |
| Founded | 2012 |
| Industry | Biotechnology Research |
Looking for a particular LabGenius Therapeutics employee's phone or email?
James Field is the CEO and Founder of LabGenius Therapeutics.
50 people are employed at LabGenius Therapeutics.